To further examine the role of TGF-βI in the expressions of OCT4 and migration-related genes, as currently there is no appropriate endometrium cell line being available, three cell lines of RL-95-2 (epithelial carcinoma), HEC1A (epithelial adenocarcinoma), and primary stromal cells (mesenchymal chocolate cyst) were used to treat with increasing dose of TGF-βI (0, 0.05, 0.1, 0.5, 1, and 5 ng/mL). The gene discussed is POU5F1; the disease is carcinoma.